Micro
Developing
Active
Pfizer CFO Dave Denton Steps Down
Gaining traction — growing article coverage and momentum.
Score
0.5
Velocity
▲ 1.0
Articles
4
Sources
2
Sentiment Timeline
Event Timeline
🤖
AI Overview
What happened: Pfizer's CFO Dave Denton announced his departure on August 15 to pursue a new opportunity in the consumer goods industry. Pfizer appointed Cecile Guegan, currently senior vice president of finance, as interim CFO. This news comes as Pfizer is considered one of the most undervalued NYSE stocks.
Market impact: Pfizer's stock fell 2.74% to $25.21 following the announcement, as investors focused on the 2026 outlook and leadership continuity. The CFO transition may test confidence in Pfizer's long-term guidance and strategy.
What to watch next: Pfizer's Q2 earnings report on July 28 will provide insight into the company's financial health and guidance under interim CFO Guegan. Additionally, investors will closely monitor any updates on Pfizer's 2026 outlook during the Q2 earnings call.
Market impact: Pfizer's stock fell 2.74% to $25.21 following the announcement, as investors focused on the 2026 outlook and leadership continuity. The CFO transition may test confidence in Pfizer's long-term guidance and strategy.
What to watch next: Pfizer's Q2 earnings report on July 28 will provide insight into the company's financial health and guidance under interim CFO Guegan. Additionally, investors will closely monitor any updates on Pfizer's 2026 outlook during the Q2 earnings call.
AI Overview as of Jun 22, 2026
Timeline
Last UpdatedJun 18, 2026